- Home
- AVIR vs STXS Comparison
AVIR vs STXS Comparison
Compare AVIR & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVIR | STXS |
|---|---|---|
| Founded | 2012 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.7M | 210.0M |
| IPO Year | 2020 | 2004 |
Fundamental Metrics
Financial Performance| Metric | AVIR | STXS |
|---|---|---|
| Price | $3.18 | $2.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | $4.00 |
| AVG Volume (30 Days) | 415.4K | ★ 615.6K |
| Earning Date | 11-12-2025 | 11-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $30,075,000.00 |
| Revenue This Year | N/A | $24.48 |
| Revenue Next Year | N/A | $29.98 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 19.62 |
| 52 Week Low | $2.46 | $1.54 |
| 52 Week High | $4.02 | $3.59 |
Technical Indicators
Market Signals| Indicator | AVIR | STXS |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 45.52 |
| Support Level | $2.99 | $2.34 |
| Resistance Level | $3.24 | $2.44 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 79.03 | 65.00 |
Price Performance
Historical ComparisonAbout AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.